#	Pagina
attuale pagina	/open-h2020/projects/199344/index.html

Opendata, web and dolomites

LeukoPredict

LeukoPredict: an in vitro system predicting and monitoring the therapeutic response of patients in the cure of Chronic Myeloid Leukemia (CML).

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

LeukoPredict project word cloud

Explore the words cloud of the LeukoPredict project. It provides you a very rough idea of what is the project "LeukoPredict" about.

resistance personalized monitor prescribe chronic run blood threatening inhibitor healthcare course kit diagnostic 12000 leukemia disease capability gold maximal patients cml imatinib standard potent 30 active approximately alternative myelogenous initiation tumorigenic abnormally life therapy cells introduction caused recognize display aggressive drugs usa leukopredict abl therapeutic sustained survival occurrence beginning revolutionized resistant cancer efficacy confers acquired transforming newly bcr rationally clinicians limit protein

Project "LeukoPredict" data sheet

The following table provides information about the project.

Coordinator	PALADIN DINO Organization address address: VIA FORMIS ACHILLE 8 city: PADOVA postcode: 35129 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Project website	http://www.leukopredict.com/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2015
Funding Scheme	SME-1
Starting year	2016
Duration (year-month-day)	from 2016-02-01 to 2016-07-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	PALADIN DINO PALADIN DINO Organization address address: VIA FORMIS ACHILLE 8 city: PADOVA postcode: 35129 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (PADOVA)	coordinator	50˙000.00

Map

Project objective

Chronic Myelogenous Leukemia (CML) is a blood cancer that affects every year more that 12000 patients in Europe and in the USA. Most CML cases are caused by Bcr-Abl, an abnormally active protein that confers tumorigenic capability to blood cells. The introduction of Imatinib, a Bcr-Abl potent inhibitor, revolutionized CML therapy, transforming this life-threatening cancer into a controllable disease. Approximately 30% of patients, however, display resistance to Imatinib and develop aggressive blood cancer. Here we propose a diagnostic kit (LeukoPredict) aimed to recognize resistant patients before the beginning of Imatinib therapy and address them to a personalized therapeutic alternative. Moreover, this test will be able to monitor the occurrence of newly acquired resistance after therapy initiation, allowing clinicians to prescribe only those drugs that demonstrate maximal efficacy. In the long run, we expect that LeukoPredict will become the gold standard to rationally define the CML therapeutic course, improve the survival of patients and limit the costs sustained by the healthcare system.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LEUKOPREDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LEUKOPREDICT" are provided by the European Opendata Portal: CORDIS opendata.